163719-70-8

Basic information

• Product Name: ETHYL 3-ISOPROPYL-1,2,4-OXADIAZOLE-5-CARBOXYLATE
• Synonyms: ETHYL 3-ISOPROPYL-1,2,4-OXADIAZOLE-5-CARBOXYLATE;3-iso-Propyl-1,2,4-oxadiazole-5-carboxylic acid ethyl ester;Ethyl 3-(propan-2-yl)-1,2,4-oxadiazole-5-carboxylate
• CAS NO: 163719-70-8
• Molecular Formula: C8H12N2O3
• Molecular Weight: 184.2
• Mol File: 163719-70-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 263.2±23.0 °C(Predicted)
• Appearance: /
• Density: 1.128±0.06 g/cm3(Predicted)
• PKA: -3.06±0.30(Predicted)
• CAS DataBase Reference: ETHYL 3-ISOPROPYL-1,2,4-OXADIAZOLE-5-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-ISOPROPYL-1,2,4-OXADIAZOLE-5-CARBOXYLATE(163719-70-8)
• EPA Substance Registry System: ETHYL 3-ISOPROPYL-1,2,4-OXADIAZOLE-5-CARBOXYLATE(163719-70-8)

Safety Data

• Hazardous Substances Data: 163719-70-8(Hazardous Substances Data)

Upstream product

• 35613-84-4 isobutyramide oxime 
• 4755-77-5 Ethyl oxalyl chloride 
• 849833-56-3 N'-hydroxy-2-methylpropanimidamide 

Downstream Products

• 944906-38-1 3-Isopropyl-1,2,4-oxadiazole-5-carboxylic acid 

Relevant articles and documents

COMPOUNDS AS HEPATITIS C INHIBITORS AND USES THEREOF IN MEDICINE

Provided herein are compounds as hepatitis C inhibitors and uses thereof in medicine. Specifically, provided herein is a compound of Formula (I) or a stereoisomer, a tautomer, an enantiomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or hepatitis C diseases. Also provided herein are a pharmaceutically acceptable composition containing such compound and a method of treating HCV infection or hepatitis C diseases comprising administering the compound or pharmaceutical composition thereof disclosed herein.

ANDROGEN RECEPTOR MODULATING CARBOXAMIDES

Compounds of formula (I) wherein Rx, Rz, R9, R10, R14, R14', R15, R15', A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are particularly useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.